ADOPORT

This brand name is authorized in Spain, France, Italy, Turkey, United Kingdom

Active ingredients

The drug ADOPORT contains one active pharmaceutical ingredient (API):

1 Tacrolimus UNII WM0HAQ4WNM - TACROLIMUS

Tacrolimus is a highly potent immunosuppressive agent. In particular, tacrolimus inhibits the formation of cytotoxic lymphocytes, which are mainly responsible for graft rejection. Tacrolimus suppresses T-cell activation and T-helper-cell dependent B-cell proliferation, as well as the formation of lymphokines (such as interleukins-2, -3, and γ-interferon) and the expression of the interleukin-2 receptor. Read about Tacrolimus

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ADOPORT Capsule, hard	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AD02	Tacrolimus	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AD Calcineurin inhibitors
Discover more medicines within L04AD02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 71673, 71674, 71675, 79456
Country: FR	Base de données publique des médicaments	Identifier(s): 61964294, 66927104, 68176916, 68955248
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 180443, 180445, 180447, 180449, 288007, 288010, 299563, 299564
Country: IT	Agenzia del Farmaco	Identifier(s): 041180062, 041180187, 041180264
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699516154547, 8699516154554, 8699516154561